PMID- 26865535
OWN - NLM
STAT- MEDLINE
DCOM- 20171031
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 18
IP  - 6
DP  - 2016 Jun
TI  - Comparison of alogliptin and glipizide for composite endpoint of glycated 
      haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes 
      mellitus.
PG  - 623-7
LID - 10.1111/dom.12643 [doi]
AB  - This was a post hoc analysis of a 2-year, double-blind study of 2639 patients 
      with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin 
      monotherapy, which assessed achievement of a composite endpoint of sustained 
      glycated haemoglobin (HbA1c) reduction (</=7.0% at week 104 or >/=0.5% decrease from 
      baseline) with no weight gain and no hypoglycaemic events with alogliptin 12.5 
      and 25 mg daily or glipizide (</=20 mg daily), each added to metformin. With an 
      HbA1c target of </=7.0%, 24.2 and 26.9% of patients treated with alogliptin 12.5 
      and 25 mg, respectively, achieved the composite endpoint versus 10.7% of patients 
      treated with glipizide (both p < 0.001). With a criterion of >/=0.5% decrease in 
      HbA1c, the composite endpoint was reached in 22.5, 25.2 and 10.4% of patients 
      treated with alogliptin 12.5 mg, alogliptin 25 mg and glipizide, respectively. 
      Odds ratios for achieving the composite endpoint favoured alogliptin in the 
      primary analysis set and in all subgroups of patients. Patients with T2DM failing 
      metformin monotherapy were more likely to achieve sustained glycaemic control 
      with no hypoglycaemia or weight gain at 2 years with alogliptin than with 
      glipizide.
CI  - (c) 2016 John Wiley & Sons Ltd.
FAU - Del Prato, S
AU  - Del Prato S
AD  - Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy.
FAU - Fleck, P
AU  - Fleck P
AD  - Takeda Global Research & Development Center, Inc., Deerfield, IL, USA.
FAU - Wilson, C
AU  - Wilson C
AD  - Takeda Global Research & Development Center, Inc., Deerfield, IL, USA.
FAU - Chaudhari, P
AU  - Chaudhari P
AD  - Takeda Global Research & Development Center, Inc., Deerfield, IL, USA.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160331
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 56HH86ZVCT (Uracil)
RN  - 9100L32L2N (Metformin)
RN  - JHC049LO86 (alogliptin)
RN  - X7WDT95N5C (Glipizide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Drug Therapy, Combination
MH  - Endpoint Determination
MH  - Female
MH  - Glipizide/*administration & dosage/adverse effects
MH  - Glycated Hemoglobin/*drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Male
MH  - Metformin/administration & dosage/adverse effects
MH  - Middle Aged
MH  - Piperidines/*administration & dosage/adverse effects
MH  - Treatment Outcome
MH  - Uracil/administration & dosage/adverse effects/*analogs & derivatives
MH  - Weight Gain/*drug effects
MH  - Young Adult
OTO - NOTNLM
OT  - DPP-4 inhibitor
OT  - alogliptin
OT  - composite endpoint
OT  - efficacy
OT  - glipizide
OT  - hypoglycaemia
OT  - type 2 diabetes
OT  - weight gain
EDAT- 2016/02/13 06:00
MHDA- 2017/11/01 06:00
CRDT- 2016/02/12 06:00
PHST- 2015/11/23 00:00 [received]
PHST- 2015/12/14 00:00 [revised]
PHST- 2016/02/02 00:00 [accepted]
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2017/11/01 06:00 [medline]
AID - 10.1111/dom.12643 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2016 Jun;18(6):623-7. doi: 10.1111/dom.12643. Epub 2016 Mar 
      31.